Question special

A very interesting study published by your group (Annals of Emergency Medicine, 2008) showed that a singular procalcitonin value in the ED outperformed classical clinical rules for CAP (PSI or CURB-65) in predicting 30-day mortality, specifically in high-risk patients. In ProACT, there was a relationship between procalcitonin tier and ICU admission (and SIRS, as has been mentioned before) shown in Table S3. Finally, although this study did not show differences in mortality between procalcitonin tiers, it was not powered for it in the first place.

Adding another factor to such tools might turn out to be cost-ineffective, but literature about it is growing. I wonder about a particular situation evidenced by the authors in the above article: high risk predicting tools (i.e., PSI IV-V) and procalcitonin <0.1. Pardon the lack of specific context but, could that change our approach to that particular patient?